readthroughSign in
CompanyAEONNYSEAliso Viejo, CA

AEON Biopharma, Inc.

AEON Biopharma develops ABP-450, a botulinum toxin biosimilar targeting therapeutic indications including movement disorders and pain conditions.

SCHEDULE 13GNov 16Latest SEC filing
Nov 16Latest story